ClinicalTrials.Veeva

Menu
C

Conquest Research | Winter Park, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Donanemab
LY3002813
Buntanetap
Troriluzole
Dihydroergotamine
SEL-212
Teriflunomide
ABBV-552
ABBV-916
ACU193

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

44 of 63 total trials

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Enrolling
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo (semaglutide)
Drug: Semagludtide

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Enrolling
Alzheimer's Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheime...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: JNJ-63733657
Drug: Placebo
Locations recently updated

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (A...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: LY3454738

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: LY3972406

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's d...

Enrolling
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Enrolling
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and f...

Enrolling
Alzheimer Disease
Drug: ACU193
Drug: Placebo

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.The main objectives o...

Active, not recruiting
Spondyloarthritis
Drug: Placebo
Drug: Upadacitinib

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting
Parkinsons Disease
Drug: Prasinezumab
Drug: Placebo

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling
Gout
Drug: Methotrexate
Biological: Pegloticase

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid...

Enrolling
Rheumatoid Arthritis
Drug: LY3871801
Drug: Placebo

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intra...

Enrolling
Alzheimers Disease
Drug: Placebo
Drug: RO7126209

Trial sponsors

Lilly logo
Novartis logo
AbbVie logo
A
Biohaven logo
Cognito Therapeutics logo
LG Chem logo
Novo Nordisk logo
Pfizer logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems